$9.710
+0.743 (+7.65%)收盤時
- High
- 9.750
- Open
- 9.230
- VWAP
- 9.56
- Vol
- 34.23K
- Mkt Cap
- 102.46M
- Low
- 9.230
- Amount
- 327.38K
- EV/EBITDA, TTM
- 0.58
Kyntra Bio, Inc., formerly FibroGen, Inc., is a biopharmaceutical company. The Company is focused on development of novel therapies in oncology and rare disease. The Company continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.
Analyst Ratings (7)
H.C. Wainwright
$43
2025-08-07
H.C. Wainwright
2025-08-07
目標價
$43
HC Wainwright & Co.
$10
2025-03-18
HC Wainwright & Co.
2025-03-18
目標價
$10
HC Wainwright & Co.
$10
2025-02-20
HC Wainwright & Co.
2025-02-20
目標價
$10
B of A Securities
$2
2023-08-08
B of A Securities
2023-08-08
目標價
$2
Raymond James
—
2023-06-27
Raymond James
2023-06-27
目標價
—
估值指標
事件時間軸
資訊
2.002-23GlobenewswireFG-3246 and Enzalutamide Combination Therapy Shows Promising Results
9.002-23NewsfilterFG-3246 and Enzalutamide Combination Therapy Shows Promising Results
9.012-15GlobenewswireFibroGen Receives FDA Orphan Drug Designation for Roxadustat in MDS Treatment
- 9.012-15Newsfilter
FibroGen Receives FDA Orphan Drug Designation for Roxadustat, Plans Phase 3 Submission in Q4 2025
9.012-15NASDAQ.COMFibroGen: Roxadustat Receives Orphan Drug Designation from FDA for MDS
FGEN FAQ — answered by Alphio AI
Kyntra Bio, Inc., formerly FibroGen, Inc., is a biopharmaceutical company. The Company is focused on development of novel therapies in oncology and rare disease. The Company continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
7 analysts cover FGEN: 5 rate it Buy, 2 Hold and 0 Sell. The average price target is 43.00.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。